parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
Published 4 years ago • 188 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
4:25
update on momelotinib for myelofibrosis
-
5:24
krt‑232: first-in-class mdm2i for myelofibrosis r/r to jak inhibitor therapy
-
1:06
fedratinib: mpn-associated myelofibrosis
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
3:19
finding novel targets for myelofibrosis from animal models
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
1:20
to jaki or not to jaki - treating early mf
-
4:31
driver mutations in mpns and their impact on prognosis: jak2, mpl, and calr
-
9:25
mgus diagnosis: a step-by-step approach
-
3:38
what is the difference between autologous and allogeneic transplant?
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
5:07
daratumumab in the management of al amyloidosis
-
1:53
the future of multiple myeloma treatment
-
1:52
cytoreductive therapy for patients with pv
-
2:20
ultra high-risk myeloma
-
8:34
hct in mds: cell source and conditioning type
-
5:18
upfront treatment in transplant candidates
-
0:52
tocilizumab for aa amyloidosis
-
1:47
shared treatment decision-making
-
3:28
molecular prognostication in smm
-
4:16
novel therapies for mpns